celecoxib oral

P1, N=15, Recruiting, C17 Council | Not yet recruiting --> Recruiting

P2, N=4, Completed, Leidos Life Sciences | Active, not recruiting --> Completed | N=2000 --> 4

A nuclear factor-kappa B (NF-κB) inhibitor, BAY11-7082, and a cyclooxygenase 2 (COX2) inhibitor, celecoxib, significantly inhibited PGE2 secretion, indicating that NF-κB and COX2 played a crucial role in reovirus-induced PGE2 production. These results indicate that reovirus replication in tumor cells is important for reovirus-induced PGE2 production. Attention should be paid to possible PGE2 production in tumors following reovirus treatment.

P1/2, N=80, Recruiting, Tanta University | Not yet recruiting --> Recruiting

Observational studies have associated use of aspirin and selective cyclooxygenase inhibitors with decreased recurrence and improved survival in patients with colon cancer...This was a post hoc analysis of the phase 3 Cancer and Leukemia Group B (now Alliance)/Southwest Oncology Group 80702 randomized clinical trial (2010-2015) assessing adjuvant celecoxib vs placebo and 3 vs 6 months of adjuvant 5-fluorouracil, leucovorin, and oxaliplatin for stage III colon cancer...The findings of this post hoc analysis suggest that ctDNA status has the potential to inform clinical decision-making among patients with stage III colon cancer who should consider adjuvant celecoxib in addition to conventional chemotherapy. ClinicalTrials.gov Identifier: NCT01150045.

P1/2, N=80, Not yet recruiting, Tanta University

P2, N=270, Recruiting, Sun Yat-sen University | N=150 --> 270

CDS should be considered in cases of acute pain in the neck or occipital regions. Moreover, prompt computed tomography of the cervical vertebrae may guide early diagnosis and avoid unnecessary invasive procedures or administration of antibiotics.

This study underscored COX-2 as a critical regulator of inflammatory microenvironment and cancer progression in ESCA, supporting its potential as both a prognostic biomarker and therapeutic target. The use of COX-2 inhibitors, such as celecoxib, holds promise for improving patient outcomes in ESCA and other COX-2-associated cancers.

The TNF-α inhibitor Etanercept significantly improves cerebral hemodynamics and cerebrovascular reserve function in elderly RA patients, potentially by suppressing systemic inflammation and improving vascular endothelial function.

Notable, compound 6g exhibited better inhibitory potency against IL-6 expression compared to the anti-inflammatory drugs dexamethasone and Celecoxib. These findings strongly support the potential of compound 6g as a promising therapeutic candidate for mitigating secondary inflammation in SCI.

P2, N=21, Suspended, New York State Psychiatric Institute | Trial completion date: Aug 2025 --> Aug 2026 | Trial primary completion date: Aug 2025 --> Aug 2026